Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

JAK inhibitors show promise for treating alopecia areata but have serious side effects.

Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.

Quetiapine may cause hair loss.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Inhaling medicine may reduce side effects and improve treatment for a major lung cancer type.

Baricitinib helps regrow hair in teens with severe alopecia areata.

JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.

Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.

Tislelizumab can cause cutaneous lupus erythematosus.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

Photodynamic therapy improved skin issues from sorafenib when other treatments failed.

Finasteride may improve prostate cancer treatment outcomes.

DHL-HisZnNa may help reduce hair loss from chemotherapy, but more research is needed.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

The compound 4c showed strong potential as an anticancer agent.

Platelet-rich plasma doesn't prevent hair loss from chemotherapy, and mononuclear cells only help against hair loss from one specific chemotherapy drug.